🇺🇸 FDA
Patent

US 12409224

Compositions and methods for the treatment of VEN/AZA resistant acute myeloid leukemia

granted A61KA61K40/11A61K40/15

Quick answer

US patent 12409224 (Compositions and methods for the treatment of VEN/AZA resistant acute myeloid leukemia) held by The Regents of the University of Colorado, a Body Corporate expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K40/11, A61K40/15, A61K40/31, A61K40/421